Market Research Firm Identifies Ten Key Cancer Drugs
Market Research Intellect has released a report identifying ten significant cancer drugs and their developers. The report covers the growth of the global anticancer drugs market through 2030.
Market Research Intellect has identified ten key anticancer drugs and the companies developing them in the global market. The firm's report, "Global Anticancer Drugs Market Size and Forecast," examines the industry's development and estimates its growth through 2030.
The companies highlighted in the report as central to anticancer drug development include F. Hoffmann-La Roche, Eli Lilly and Company, Celgene Corporation, Novartis, Pfizer, Amgen, Bayer, AstraZeneca Pharma, Takeda Pharmaceutical, and Merck. These firms represent a significant portion of the anticancer drug market, which is benefiting from technological advancements.
The anticancer drug market is expanding due to technological progress. Cancer is a disease characterized by the spread of malignant cells that impair bodily functions. Anticancer drugs, chemically classified into categories such as alkylating agents, antimetabolites, natural products, and hormones, aim to combat these cells. Therapeutically, these drugs can be cytotoxic, hormonal, or targeted, including small molecule inhibitors and monoclonal antibodies.
Companies like F. Hoffmann-La Roche focus on developing diagnostics and drugs for various serious conditions, including cancer. Eli Lilly and Company holds a strong position in oncology and immunology. Novartis and Pfizer are major global pharmaceutical companies bringing a wide range of treatments to market. Amgen specializes in biotechnology-based drugs, while Bayer's healthcare division covers cancer treatment. AstraZeneca Pharma and Takeda Pharmaceutical are engaged in research and development of new therapies, with Merck also being a key player in the sector.